Bridgeway Capital Management’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Bridgeway Capital Management’s Portfolio DBTX Stock Details DBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-119,100	Closed	-$459K	–	1454
2023 Q2	$459K	Hold	119,100	–	–	0.01%	925
2023 Q1	$360K	Buy	119,100 +7,118	+6%	+$24.6K	0.01%	963
2022 Q4	$230K	Buy	111,982 +50,000	+81%	+$152K	0.01%	1055
2022 Q3	$214K	Sell	61,982 -50,000	-45%	-$228K	0.01%	1129
2022 Q2	$471K	Sell	111,982 -2,946	-3%	-$6.96K	0.01%	892
2022 Q1	$349K	Hold	114,928	–	–	0.01%	1031
2021 Q4	$534K	Hold	114,928	–	–	0.01%	966
2021 Q3	$886K	Buy	114,928 +42,928	+60%	+$328K	0.02%	859
2021 Q2	$619K	Buy	+72,000	New	+$635K	0.01%	1010

Other funds holding DBTX

ACA

Atlas Capital Advisors Jackson, Wyoming $914M AUM

Bridgeway Capital Management's DBTX Position: Q3 2023 in Review

Bridgeway Capital Management sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q3 2023, closing a stake of 119,100 shares — an estimated $459K sold.

Bridgeway Capital Management first reported a position in DBTX in Q2 2021 and held it in 9 quarters. The position peaked at $886K in Q3 2021. 1 fund tracked by Wall St. Rank holds DBTX as of Q3 2023.

Bridgeway Capital Management reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Bridgeway Capital Management sold 119,100 Decibel Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $459K.
Bridgeway Capital Management first reported a position in Decibel Therapeutics, Inc. Common Stock in Q2 2021 and held it in 9 quarters.
Bridgeway Capital Management's Decibel Therapeutics, Inc. Common Stock position peaked at $886K in Q3 2021.
1 fund tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Bridgeway Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.